EPZ005687 is a potent inhibitor of PRC2 with IC50 value of 54±5nM (measured by PRC2 enzymatic activity), with selectivity >500-fold over other HMTs, ~50-fold over EZH1. EPZ005687 can specifically inhibit H3K27 methylation.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
产品名称 | BET ↓ ↑ | bromodomain ↓ ↑ | BRPF ↓ ↑ | CBP/beta-catenin ↓ ↑ | p300/CBP ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MS436 |
++
BRD4 (1), Ki: <0.085 μM BRD4 (2), Ki: 0.34 μM |
99%+ | |||||||||||||||||
CPI-203 |
+++
BRD4, IC50: 37 nM |
98+% | |||||||||||||||||
GSK1324726A |
+++
BRD4, IC50: 22 nM BRD2, IC50: 31 nM |
99%+ | |||||||||||||||||
PFI-1 |
++
BRD4, IC50: 0.22 μM BRD2, IC50: 98 nM |
98% | |||||||||||||||||
Apabetalone |
+
BD2, IC50: 0.51 μM |
99% | |||||||||||||||||
(+)-JQ1 |
+++
BRD4 (1), IC50: 77 nM BRD4 (2), IC50: 33 nM |
98% | |||||||||||||||||
I-BET151 |
+
BRD4, IC50: 0.5 μM BRD3, IC50: 0.25 μM |
98% | |||||||||||||||||
Molibresib |
+++
BET proteins, IC50: 35 nM |
99%+ | |||||||||||||||||
I-BRD9 |
+++
BRD4, pIC50: 5.3 BRD9, pIC50: 7.3 |
99%+ | |||||||||||||||||
BI-7273 |
++++
BRD7, IC50: 117 nM BRD9, IC50: 19 nM |
99+% | |||||||||||||||||
Pelabresib |
+++
BRD4-BD1, IC50: 39 nM |
98% | |||||||||||||||||
ARV-825 |
+++
BRD4 BD2, Kd: 28 nM BRD4 BD1, Kd: 90 nM |
99%+ | |||||||||||||||||
Birabresib | 99%+ | ||||||||||||||||||
BI 2536 |
+++
BRD4, Kd: 37 nM |
c-Myc | 99%+ | ||||||||||||||||
Bromosporine |
++
BRD2, IC50: 0.29 μM BRD9, IC50: 0.122 μM |
++++
CECR2, IC50: 17 nM |
99%+ | ||||||||||||||||
XMD8-92 |
++
BRD4 (1), Kd: 170 nM |
99%+ | |||||||||||||||||
Mivebresib | ✔ | 99%+ | |||||||||||||||||
BI-9564 |
++++
BRD7, Kd: 73 nM BRD9, Kd: 5.9 nM |
++
CECR2, Kd: 77 nM |
98% | ||||||||||||||||
AZD5153 6-Hydroxy-2-naphthoic acid |
++++
FL-BRD4, IC50: 5 nM |
99%+ | |||||||||||||||||
PLX51107 |
++++
BRD4 BD2, Kd: 1.7 nM BRD3 BD1, Kd: 2.1 nM |
99%+ | |||||||||||||||||
FL-411 |
+
BRD4(1), IC50: 0.43 μM |
99%+ | |||||||||||||||||
ABBV-744 | ✔ | 99%+ | |||||||||||||||||
dBET6 |
++++
BRD4, IC50: 14 nM |
99%+ | |||||||||||||||||
dBET1 |
++++
BRD4, IC50: 20 nM |
99%+ | |||||||||||||||||
MZ1 |
++++
Brd2(BD2), Kd: 62 nM Brd3(BD2), Kd: 13 nM |
99%+ | |||||||||||||||||
dBET57 |
+
BRD4BD1, DC50: 500 nM |
99%+ | |||||||||||||||||
SF2523 |
+
BRD4, IC50: 241 nM |
DNA-PK | 99%+ | ||||||||||||||||
INCB054329 |
++++
BRD3-BD1, IC50: 9 nM BRD4-BD1, IC50: 119 nM |
99% | |||||||||||||||||
INCB-057643 | ✔ | 99%+ | |||||||||||||||||
(E/Z)-ZL0420 |
+++
BRD4 BD2, IC50: 32 nM BRD4 BD1, IC50: 27 nM |
99%+ | |||||||||||||||||
BMS-986158 | ✔ | 99%+ | |||||||||||||||||
BRD4 Inhibitor-10 |
++++
BRD4-BD1, IC50: 5 nM BRD4-BD2, IC50: 41 nM |
97% | |||||||||||||||||
A1874 | ✔ | 99%+ | |||||||||||||||||
Y06036 |
++
BRD4 (1), Kd: 82 nM |
99%+ | |||||||||||||||||
Alobresib | ✔ | NF-κB | 98% | ||||||||||||||||
ODM-207 | ✔ | 99% | |||||||||||||||||
GSK778 |
+++
BRD4-BD1, IC50: 143 nM BRD2-BD1, IC50: 75nM |
97% | |||||||||||||||||
SRX3207 |
+
BRD42, IC50: 3070 nM BRD41, IC50: 3070 nM |
Syk | 98% | ||||||||||||||||
GSK046 |
+++
BRD4BD2, IC50: 214 nM BRD3BD2, IC50: 98 nM |
98% | |||||||||||||||||
GSK620 | ✔ | 97% | |||||||||||||||||
Thalidomide-NH-C4-NH-Boc | ✔ | 98% | |||||||||||||||||
Trotabresib | ✔ | 99% | |||||||||||||||||
NHWD-870 | ✔ | 98% | |||||||||||||||||
CFT8634 |
++++
BRD9, DC50: 3 nM |
98% | |||||||||||||||||
GSK2801 |
++
BAZ2B, Kd: 136 nM BAZ2A, Kd: 257 nM |
99%+ | |||||||||||||||||
KG-501 | ✔ | 99%+ | |||||||||||||||||
UNC 669 |
+
L3MBTL4, IC50: 6 μM L3MBTL3, IC50: 35 μM |
98% | |||||||||||||||||
PFI-3 |
+++
SMARCA4, Kd: 55 nM SMARCA2A, Kd: 72 nM |
99%+ | |||||||||||||||||
UNC1215 |
+++
L3MBTL3- D274A, IC50: 3.5 μM L3MBTL3, IC50: 120 nM |
99%+ | |||||||||||||||||
EED226 |
++
EED, Kd: 82 nM PRC2, Kd: 114 nM |
99%+ | |||||||||||||||||
BRD9539 | ✔ | 98% | |||||||||||||||||
UNC926 |
+
L3MBTL1, Kd: 3.9 μM |
99% | |||||||||||||||||
666-15 |
++
CREB, IC50: 81 nM |
99%+ | |||||||||||||||||
UNC6852 |
+
EED, IC50: 247 nM |
98% | |||||||||||||||||
BAZ1A-IN-1 |
+
BAZ1A, Kd: 0.52 μM |
99%+ | |||||||||||||||||
PFI-4 |
++
BRPF2, IC50: 7.9 μM BRPF1, IC50: 80 nM |
99%+ | |||||||||||||||||
OF-1 |
++
BRPF2, Kd: 500 nM BRPF1B, Kd: 100 nM |
99%+ | |||||||||||||||||
GSK-5959 |
++
BRPF2, pIC50: 5.2 BRPF3, pIC50: 7.1 |
99% | |||||||||||||||||
GSK6853 |
++++
BRPF1, pIC50: 8.1 |
99%+ | |||||||||||||||||
NI-42 |
++++
BRPF1, IC50: 48 nM BRPF3, IC50: 260 nM |
99%+ | |||||||||||||||||
E-7386 |
+++
CBP/beta-catenin, IC50: 0.0484 μM |
97% | |||||||||||||||||
I-CBP112 |
++
CBP, Kd: 151 nM p300, Kd: 167 nM |
98+% | |||||||||||||||||
Histone Acetyltransferase Inhibitor II |
+
p300, IC50: 5 μM |
98% | |||||||||||||||||
C646 |
+
p300/CBP, Ki: 400 nM |
99%+ | |||||||||||||||||
Anacardic Acid |
+
PCAF, IC50: 5 μM p300/CBP, IC50: 8.5 μM |
99%+ | |||||||||||||||||
SGC-CBP30 |
++++
CREBBP, IC50: 21 nM EP300, IC50: 38 nM |
99%+ | |||||||||||||||||
Nordihydroguaiaretic acid | ✔ | HER2,IGF-1R | 99%+ | ||||||||||||||||
Curcumin |
+
p300, IC50: ~25 μM |
Ferroptosis,Nrf2,NF-κB | 98% | ||||||||||||||||
PF-CBP1 HCl |
++
CREBBP, IC50: 125nM p300/CBP, IC50: 363nM |
97% | |||||||||||||||||
CPI-637 |
+++
EP300, IC50: 0.051 μM CBP, IC50: 0.03 μM |
99%+ | |||||||||||||||||
Foscenvivint | ✔ | β-catenin | 99%+ | ||||||||||||||||
A-485 |
++
p300 HAT, IC50: 0.06 μM |
99%+ | |||||||||||||||||
GNE-781 |
+
BRD4(1), IC50: 5100 nM |
++++
CBP, IC50: 0.94 nM |
98% | ||||||||||||||||
NEO2734 |
+++
BET, IC50: <30 nM |
+++
p300/CBP, IC50: <30 nM |
99%+ | ||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
产品名称 | Histone Methyltransferase ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD4770 | ✔ | 99%+ | |||||||||||||||||
UNC1999 |
+++
EZH1, IC50: 45 nM EZH2, IC50: 2 nM |
99%+ | |||||||||||||||||
EPZ005687 |
++
EZH2, Ki: 24 nM |
98+% | |||||||||||||||||
EPZ015666 |
+++
PRMT5, Ki: 5 nM |
99%+ | |||||||||||||||||
3-Deazaneplanocin A HCl |
++++
S-adenosylhomocysteine hydrolase, Ki: 50 pM |
99%+ | |||||||||||||||||
Tazemetostat |
+++
EZH2, IC50: 11 nM EZH2, Ki: 2.5 nM |
98% | |||||||||||||||||
GSK126 |
++
EZH2, IC50: 9.9 nM |
99%+ | |||||||||||||||||
MI-3 |
+
Menin-MLL, IC50: 648 nM |
98% | |||||||||||||||||
MM-102 |
++
MLL1, IC50: 0.4 μM |
99% | |||||||||||||||||
EI1 |
++
Ezh2 (wild-type), IC50: 15 nM EZH2 (Y641F), IC50: 13 nM |
98% | |||||||||||||||||
SGC0946 |
++++
DOT1L, IC50: 0.3 nM |
99%+ | |||||||||||||||||
PFI-2 HCl |
++++
SETD7, Ki: 0.33 nM SETD7, IC50: 2 nM |
99%+ | |||||||||||||||||
Pinometostat |
++++
DOT1L, Ki: 80 pM |
99%+ | |||||||||||||||||
EPZ004777 |
+++
DOT1L, IC50: 0.4 nM |
99%+ | |||||||||||||||||
Entacapone |
++
COMT, IC50: 151 nM |
95% | |||||||||||||||||
UNC0379 |
+
SETD8, IC50: 7.9 μM |
99%+ | |||||||||||||||||
Menin-MLL inhibitor MI-2 |
+
Menin-MLL, IC50: 446 nM |
98% | |||||||||||||||||
GSK343 |
+++
EZH1, IC50: 240 nM EZH2, IC50: 4 nM |
99%+ | |||||||||||||||||
BIX-01294 3HCl |
+
G9a, IC50: 2.7 μM |
99%+ | |||||||||||||||||
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 |
靶点 |
|
描述 | EZH2 is the enzymatically active core subunit of the PRC2 complex, which methylates H3K27 and facilitates chromatin compaction and gene silencing. EPZ005687 is a potent inhibitor of PRC2 with IC50 value of 54±5nM (measured by PRC2 enzymatic activity), with selectivity >500-fold over other HMTs, ~50-fold over EZH1. EPZ005687 can specifically inhibit H3K27 methylation. Treatment with EPZ005687 (0.044-5.6uM) for 96h shows a dose-dependent decrease in H3K27me3 in wild-type EZH2 lymphoma cell line OCI-lY19. EPZ005687 can decrease proliferation in a dose (<8.3uM) and time (<11 days) dependent manner in mutant EZH2 lymphoma cells, WSU-DLCL2 (Y641F) and pfeiffer (A677G), but not wild-type cells, OCI-lY19 cell line. Treatment in mutant EZH2 lymphoma cells, WSU-DLCL2 (Y641F), with EPZ005687 (0.2-6uM) for 4 days resulted in a dose-dependent increase of accumulation in G1[1]. Recently, it was found that EPZ005687 (10mg/kg, injected peritoneally, once a week for 4 weeks) can significantly inhibit the development of TAC (Transverse Aortic Constriction) -induced PAH (pulmonary artery hypertension) in an EZH2-SOD1-ROS dependent manner in male balb/c mice (6–8 weeks old) [2]. |
作用机制 | EPZ005687 is a SAM-competitive inhibitor of PRC2, which binds in the SAM pocket of the EZH2 SET domain.[1] |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
human OCI-LY19 cells | Function assay | 96 h | Inhibition of wild-type EZH2 in human OCI-LY19 cells assessed as reduction of H3K27me3 level after 96 hrs by ELISA assay, IC50=0.08 μM | 25406853 |
Dose | Mice[2] (i.p.): 10 mg/kg |
Administration | i.p. |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.85mL 0.37mL 0.19mL |
9.26mL 1.85mL 0.93mL |
18.53mL 3.71mL 1.85mL |
CAS号 | 1396772-26-1 |
分子式 | C32H37N5O3 |
分子量 | 539.668 |
别名 | |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Sealed in dry,Store in freezer, under -20°C |
溶解度 |
DMSO: 8 mg/mL(14.82 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |